Triple Negative Breast Cancer
Conditions
Brief summary
The purpose of this study is to increase survival of patients with locally advanced triple-negative breast cancer using two consequent induction preoperative chemotherapy regimens.
Detailed description
Compared to other breast cancer subtypes, patients with triple-negative breast cancer have a lower recurrence-free and overall survival, regardless of disease stage at diagnosis. That's why new approaches to treatment of this aggressive breast cancer subtype are extremely anticipated. One of the ways to improve the results of treatment of locally advanced triple-negative breast cancer is intensification of induction preoperative chemotherapy regimens. Elevation of the rate of pathological complete responses after completion of intensification induction preoperative chemotherapy enables to decrease the stage and increase survival of this aggressive breast cancer subtype. We hope to achieve more clinical and pathological treatment responses than with standard chemotherapy regimens and therefore to improve treatment outcomes of this extremely adverse group of patients.
Interventions
DRUGPaclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine
Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
Sponsors
Russian Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Female patients, age ≥18 years≤75 * Histologically confirmed invasive ER-, PR-, and HER2-negative (triple-negative) adenocarcinoma of the breast * Stages Т2-4 N 2-3 M0 * Signed inform consent
Exclusion criteria
* Previous treatment for this breast cancer * History of malignancy treated with curative intent within the previous 5 years with the exception of skin cancer, cervical carcinoma in situ, or follicular thyroid cancer. Patients with previous invasive cancers (including breast cancer) are eligible if the treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease * Pregnancy or breast-feeding * Serious concurrent diseases or conditions that may alter chemotherapy conduction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The pathological complete response rate to two consequent induction preoperative chemotherapy regimens | After 18 weeks of induction chemotherapy |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival | 3 years |
Other
| Measure | Time frame |
|---|---|
| Number of patients with 3/4 Grade CTC adverse events to assess toxicity and tolerability of the chemotherapy regimens | After 18 weeks os induction chemotherapy |
Countries
Russia
Outcome results
None listed